top of page

Irelands HPRA's: Medical Device Guide to Clinical Investigations Carried Out in Ireland

On 18th November, 2022 Irelands Health Products Regulatory Authority (HPRA) released an updated Guide related to "Clinical Investigations Carried Out in Ireland".

CLINICAL INVESTIGATION (CI) is a systematic study involving one or more human subjects that assesses the safety or performance of a medical device.


As part of this guide, the Health Products Regulatory Authority provides guidance on the legislation on clinical investigations using medical devices as well as information on how to submit applications to carry out these CIs.


In general, to conduct a CI in Ireland the applicant/company need to:

  1. Submit an application or notification to HPRA.

  2. Apply to the National Research Ethics Committee for Medical Devices (NREC-MD).

  3. Fulfill other requirements such as adverse event reporting.

If the planned modification to the CI is substantial, you must submit a notification to HPRA for assessment before making the modification.


In Ireland, all clinical investigations must receive ethics approval from the National Research Ethics Committee – Medical Devices (NREC-MD) before the CI starts. The NREC-MD review is independent from HPRA review.


The applicant/company can apply to the NREC-MD and to the HPRA at the same time or at different times, but the CI cannot start until both reviews are complete.


Click this LINK to know more about the 3 types of CI's and the Submission review process.

I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page